HPV even if I've have the shots?

I have have the first two of the three HPV shots in the series and involve to get the third one surrounded by a month, I recently found out that I could hold been exposed to HPV from intercourse, do the first shots serve as protection even if I havent finished the series?
Answers:

Labia Minora(inner oral cavity of the vagina)?

This is a trick question. The problem is that in attendance are literally DOZENS of strains of the virus; the shots only protect against the top most-likely strains (I believe it be 4 strains that were targeted) that end in cervical cancer most of the time. So if the strain of HPV that you were exposed to is one of the four to be exact guarded against by the shot, you should still have some horizontal of protection; if it was a different strain, consequently the shot would have be ineffective anyway.

But just be sure to finish out the series; never assume that your protection is automatically negated.

Augmentation?

Will females be protected against HPV and related diseases, even if they don’t achieve all three doses?

It is not on the other hand known how much protection females would draw from from receiving solely one or two doses of the vaccine. For this reason, it is totally important that females catch all three doses of the vaccine.

http://www.southernnevadahealthdistrict.

This is exactly why they want to procure the girls around 11 years old. If you're have sex, you probably already have HPV contained by your system.

Girls with breast implant please answer?

You need adjectives three injections. www.gardasil.com

Studies show for women who have already have sex then the vaccine does provide full benefits.

The vaccine single prevents two low risk HPV types 6 and 11 and two high risk HPV types 16 and 18. They are over 30 HPV types that are specific to the genital nouns.

You need to attain the 3 shot but the protections may be less. Even when getting the vaccine we stipulation to continue near our yearly Pap tryout with HPV assessment.

Here is the article on the Efficacy of the vaccine after women have be exposed to the virus.

Daily Women's Health Policy
Public Health & Education | Efficacy of HPV Vaccine Gardasil Among
Women Previously Infected With HPV Lower Than Expected, Study Says
[May 10, 2007]
The efficacy of Merck's human papillomavirus vaccine Gardasil
among women previously infected with the virus is lower than
expected, according to a study published in the May 10 issue of the
New England Journal of Medicine, the Los Angeles Times reports
(Chong/Maugh, Los Angeles Times, 5/10).

Gardasil in previous clinical trials have been shown to be 100%
significant in preventing infection near strains 16 and 18, which
together cause just about 70% of cervical cancer cases, and about 99%
influential in preventing HPV strains 6 and 11, which together with
strains 16 and 18 result in about 90% of genital wart cases, among women
not already infected beside these strains. FDA in June 2006 approved
Gardasil for sale and marketing to girls and women ages nine to 26,
and CDC's Advisory Committee on Immunization Practices following that
month voted unanimously to recommend that girls ages 11 and 12
receive the vaccine, which is given in a three-shot series (Kaiser
Daily Women's Health Policy Report, 5/1).

For the study, Laura Koutsky, an epidemiologist at the University of
Washington, and colleagues studied 12,157 women between ages 15 and
26 (Los Angeles Times, 5/10). The participants be from 13
countries, Reuters reports (Emery, Reuters, 5/10). About 93% of the
women enrolled contained by the study were not virgins when the study begin,
the USA Today reports (Rubin, USA Today, 5/10). Half of the women and
girls were given Gardasil contained by the recommended three doses over six
months and half be given a placebo, the Times reports. All the
participants be followed for three years, during which time the
researchers recorded any precancerous lesion that developed that had
a high risk of progressing into cancer (Los Angeles Times, 5/10).

Before the women received Gardasil or the placebo, they be screened
to see whether they had ever be infected by any of the four strains
of HPV targeted by the vaccine. The researchers found that less than
1% of the women have been infected beside all four strains but 27% had
be infected with at most minuscule one of the strains (USA Today, 5/10).

The study -- funded by Merck -- found that Gardasil was 98% effective
at preventing precancerous lesion of the cervix related to strains
16 and 18 among women previously uninfected with these two strains of
the virus. The efficacy of the vaccine be 44% among women previously
infected with HPV strains 16 and 18 and be 17% when all precancerous
lesion caused by vaccine and nonvaccine types be taken into
account, the study found (Carreyrou/Weinstein, Wall Street Journal,
5/10). According to the Times, the facts indicate that the vaccine is
not "living up" to its original prospects and that 129 women would
hold to be vaccinated to prevent one precancerous lesion (Los Angeles
Times, 5/10).

In a related study, Suzanne Garland of the Royal Women's Hospital in
Melbourne, Australia, and colleagues enrol 5,455 women and girls
ages 16 to 24 (Reuters, 5/10). The study found that Gardasil was 100%
contained by preventing cancer, lesions and wart among women who had never
be infected with the HPV strains targeted by the vaccine, and
efficacy be 20% among women already infected with at lowest one of
the strains (HealthDay News/Forbes, 5/9).
Comments
"It's important that women become conscious if they're sexually active,
in that's a chance they won't receive full benefit from the vaccine,"
Koutsky said (USA Today, 5/10). She added, "The overall message, in
my mind, is that among susceptible childlike women, the vaccine was
highly effectual in preventing HPV [strains] 16 or 18 precancerous
cervical lesion." W. Martin Kast -- an immunologist of the
University of Southern California's Keck School of Medicine, who was
not involved in the research -- said, "In a three-year follow-up, it
is very strong to reach statistical significance surrounded by a disease process
that takes going on for a decade to fully develop." He added, "Thus, it is
not fair to state that the vaccine is not important. It will be, but
it needs more time to materialize."

Diane Harper of Dartmouth University, who help design one of the
studies, said she is still in favor of giving Gardasil to girls
because it is safe and sound and it "protects against the main HPV unpromising actors,"
but she said that "neither physicians nor women should be lulled into
a false sense of security" by the vaccine. "I don't assume this is the
gun that is going to nick cervical cancer off the map," Harper said
(Los Angeles Times, 5/10).
NEJM Editorial, Comments
In an accompanying NEJM editorial, George Sawaya and Karen Smith-
McCune, both of the University of California-San Francisco's
Department of Obstetrics, Gynecology and Reproductive Sciences, write
that the overall efficacy of Gardasil is "modest," count that
a "cautious approach ... may be necessary in insubstantial of important
unanswered question about overall vaccine worth, duration of
protection and adverse effects that may emerge over time." The
authors write that one reason for the predetermined efficacy might be that
other cancer-causing strains of HPV might fill "the biological niche
disappeared behind after the expulsion of HPV types 16 and 18" (Wall
Street Journal, 5/10). Douglas Lowy of the National Cancer Institute,
who originally developed Gardasil, said that even if other types of
HPV proliferate, there might not be a significant increase in cancers
because the other strains are smaller quantity carcinogenic (Los Angeles Times,
5/10).

The study led by Koutsky and the study lead by Garland are available
online.
Related NEJM Perspectives, Opinion Pieces
NEJM in the